BIOMAT Database Logo BIOMAT Database Logo

A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. 2008

Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
University of Texas Health Science Center, San Antonio, Texas, USA. Langevin@UTHSCSA.edu

BACKGROUND Rebeccamycin Analogue (NSC #655649), a chemically synthesized glycosyl-dichloro-indolocarbazole derivative of rebeccamycin with topoisomerase inhibiting activity, has in vitro activity against pediatric tumor cell lines and tumor specimens including rhabdomyosarcoma, neuroblastoma, Ewing's sarcoma and medulloblastoma. METHODS The primary objective of this trial was to determine the response rate to Rebeccamycin analogue NSC #655649 in children with refractory solid and CNS tumors. Secondary objectives included further evaluation of the toxicity and pharmacokinetic profile of Rebeccamycin analogue in children with relapsed and refractory cancer. A two-stage design was used for this Phase II trial. Rebeccamycin analogue, 650 mg/m(2), was administered every 21 days, and could be escalated to 780 mg/m(2) in subsequent cycles to achieve a maximum plasma drug concentration >5 microg/ml. RESULTS From July 2000 to October 2004, 72 male and 61 female eligible patients were enrolled. Of 126 evaluable patients for response, only 4 patients had an objective response: 3 patients with rhabdomyosarcoma (1 CR and 2 PR) and 1 patient with neuroblastoma (1 PR). Grade 3 or 4 myelosuppression occurred in 81% (215/265) of patient courses and hepatotoxicity in 14% (37/265) of patient courses. Transient pancreatitis and/or elevation of amylase and lipase occurred in 6 patients. CONCLUSIONS The 15% response rate to Rebeccamycin analogue observed in patients with rhabdomyosarcoma, while of interest, is associated with significant myelosuppression. With a global response rate of 3% observed in children with relapsed CNS and non-CNS solid tumors, further development of Rebeccamycin analogue in pediatric solid tumors is not recommended.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010195 Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis. Acute Edematous Pancreatitis,Acute Pancreatitis,Pancreatic Parenchyma with Edema,Pancreatic Parenchymal Edema,Pancreatitis, Acute,Pancreatitis, Acute Edematous,Peripancreatic Fat Necrosis,Acute Edematous Pancreatitides,Acute Pancreatitides,Edema, Pancreatic Parenchymal,Edematous Pancreatitides, Acute,Edematous Pancreatitis, Acute,Fat Necrosis, Peripancreatic,Necrosis, Peripancreatic Fat,Pancreatic Parenchymal Edemas,Pancreatitides, Acute,Pancreatitides, Acute Edematous,Parenchymal Edema, Pancreatic,Peripancreatic Fat Necroses
D001855 Bone Marrow Diseases Diseases involving the BONE MARROW. Bone Marrow Disease,Disease, Bone Marrow,Diseases, Bone Marrow,Marrow Disease, Bone,Marrow Diseases, Bone
D002227 Carbazoles Benzo-indoles similar to CARBOLINES which are pyrido-indoles. In plants, carbazoles are derived from indole and form some of the INDOLE ALKALOIDS.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
December 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer.
February 2003, Investigational new drugs,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
October 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer.
November 2003, Investigational new drugs,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
In vitro antitumor activity of rebeccamycin analog (NSC# 655649) against pediatric solid tumors.
January 1998, Journal of pediatric hematology/oncology,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.
September 2010, Pediatric blood & cancer,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study.
January 2000, Journal of pediatric hematology/oncology,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
June 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
Pediatric oncology group phase II trial of amsacrine in children with solid tumors.
March 1985, Cancer treatment reports,
Anne-Marie Langevin, and Mark Bernstein, and John G Kuhn, and Susan M Blaney, and Percy Ivy, and Junfeng Sun, and Zhengjia Chen, and Peter C Adamson, and
Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.
July 2002, Clinical cancer research : an official journal of the American Association for Cancer Research,
Copied contents to your clipboard!